Format

Send to

Choose Destination
See comment in PubMed Commons below
Schizophr Res Treatment. 2012;2012:764769. doi: 10.1155/2012/764769. Epub 2012 May 7.

Role of long-acting injectable second-generation antipsychotics in the treatment of first-episode schizophrenia: a clinical perspective.

Author information

  • 1Central European Institute of Technology, Masaryk University (CEITEC-MU), Kamenice 753/5, 62500 Brno, Czech Republic.

Abstract

Approximately 80% of patients with the first-episode schizophrenia reach symptomatic remission after antipsychotic therapy. However, within two years most of them relapse, mainly due to low levels of insight into the illness and nonadherence to their oral medication. Therefore, although the formal data available is limited, many experts recommend prescribing long-acting injectable second-generation antipsychotics (mostly risperidone or alternatively paliperidone) in the early stages of schizophrenia, particularly in patients who have benefited from the original oral molecule in the past and agree to receive long-term injectable treatment. Early application of long-acting injectable second-generation antipsychotics can significantly reduce the risk of relapse in the future and thus improve not only the social and working potential of patients with schizophrenia but also their quality of life.

PMID:
22966444
PMCID:
PMC3420571
DOI:
10.1155/2012/764769
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Hindawi Publishing Corporation Icon for PubMed Central
    Loading ...
    Support Center